Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies. DMD symptom onset is in early childhood, usually between ages 2 and 3. The daughters each have a 50% chance of being carriers. Very rarely, a female can be affected by the disease. Duchenne muscular dystrophy occurs in about 1 out of every 3600 male infants. The disease primarily affects boys, but in rare cases it can affect girls. Duchenne muscular dystrophy is a form of muscular dystrophy. The main sign of muscular dystrophy is progressive muscle weakness. Specific signs and symptoms begin at different ages and in different muscle groups. No cure for DMD is known, and an ongoing medical need has been recognized by regulatory authorities. Gene therapy has shown some success. Complications includes osteoporosis, nutritional problems, cardiac complication such as cardiomyopathy, chest and breathing complication. This condition can be improved when detected as early as possible.
Cite this article:
Abhijit Pandurang Bhoyar. Duchenne Muscular Dystrophy. International Journal of Nursing Education and Research. 2021; 9(4):512-4. doi: 10.52711/2454-2660.2021.00121
Abhijit Pandurang Bhoyar. Duchenne Muscular Dystrophy. International Journal of Nursing Education and Research. 2021; 9(4):512-4. doi: 10.52711/2454-2660.2021.00121 Available on: https://ijneronline.com/AbstractView.aspx?PID=2021-9-4-31
2. https://www.medicinenet.com/duchenne_muscular_dystrophy/defi nition.htm
4. https://www.mayoclinic.org/diseases-conditions/muscular- dystrophy/symptoms-causes/syc-20375388
5. https://www.mayoclinic.org/diseases-conditions/muscular- dystrophy/diagnosis-treatment/drc-20375394
6. https://www.pfizer.com/news/press-release/press-release- detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys
7. Dany A, Barbe C, Rapin A, Réveillère C, Hardouin JB, Morrone I, et al. (November 2015). "Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease". Quality of Life Research. 24 (11): 2615–23. doi:10.1007/s11136- 015-1013-8. PMID 26141500. S2CID 25834947
8. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (May 2016). "Corticosteroids for the treatment of Duchenne muscular dystrophy". The Cochrane Database of Systematic Reviews. 5(5): CD003725. doi:10.1002/14651858.CD003725.pub4. PMID 27149418
11. "Duchenne muscular dystrophy (DMD) | Muscular Dystrophy Campaign". Muscular-dystrophy.org. Archived from the originalon 2013-01-21. Retrieved 2013-02-16.